US FDA panel endorses Pfizer's Fablyn for osteoporosis
This article was originally published in Scrip
Executive Summary
A US FDApanel has endorsed Pfizer's selective oestrogen receptor modulator (SERM) Fablyn (lasofoxifene, formerly Oporia) for the treatment of osteoporosis in postmenopausal women.